Recent advances in understanding lipodystrophy: A focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function [version 1; peer review: 3 approved]

Thiago Bruder-Nascimento, Taylor C. Kress, Eric J. Belin De Chantemele

Research output: Contribution to journalReview article

Abstract

Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.

Original languageEnglish (US)
Article number1756
JournalF1000Research
Volume8
DOIs
StatePublished - Oct 16 2019

Fingerprint

Lipodystrophy
Peer Review
Leptin
Cardiovascular Diseases
Medical problems
Therapeutics
Hormones
Insulin
Tissue
Hypertriglyceridemia
Liver Failure
Fatty Liver
Life Expectancy
Vascular Diseases
Adipocytes
Type 2 Diabetes Mellitus
Insulin Resistance
Adipose Tissue
Obesity
Hypertension

Keywords

  • Cardiomyopathy
  • Cardiovascular disease
  • Hypertension
  • Lipodystrophy
  • Metreleptin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{37f3e821567f4218a616aca86e77fff3,
title = "Recent advances in understanding lipodystrophy: A focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function [version 1; peer review: 3 approved]",
abstract = "Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.",
keywords = "Cardiomyopathy, Cardiovascular disease, Hypertension, Lipodystrophy, Metreleptin",
author = "Thiago Bruder-Nascimento and Kress, {Taylor C.} and {Belin De Chantemele}, {Eric J.}",
year = "2019",
month = "10",
day = "16",
doi = "10.12688/f1000research.20150.1",
language = "English (US)",
volume = "8",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in understanding lipodystrophy

T2 - A focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function [version 1; peer review: 3 approved]

AU - Bruder-Nascimento, Thiago

AU - Kress, Taylor C.

AU - Belin De Chantemele, Eric J.

PY - 2019/10/16

Y1 - 2019/10/16

N2 - Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.

AB - Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.

KW - Cardiomyopathy

KW - Cardiovascular disease

KW - Hypertension

KW - Lipodystrophy

KW - Metreleptin

UR - http://www.scopus.com/inward/record.url?scp=85074162403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074162403&partnerID=8YFLogxK

U2 - 10.12688/f1000research.20150.1

DO - 10.12688/f1000research.20150.1

M3 - Review article

C2 - 31656583

AN - SCOPUS:85074162403

VL - 8

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 1756

ER -